GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (NAS:MEDP) » Definitions » Cash-to-Debt

Medpace Holdings (Medpace Holdings) Cash-to-Debt : 2.99 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Medpace Holdings's cash to debt ratio for the quarter that ended in Mar. 2024 was 2.99.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Medpace Holdings could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Medpace Holdings's Cash-to-Debt or its related term are showing as below:

MEDP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04   Med: 0.23   Max: 3.52
Current: 2.99

During the past 11 years, Medpace Holdings's highest Cash to Debt Ratio was 3.52. The lowest was 0.04. And the median was 0.23.

MEDP's Cash-to-Debt is ranked better than
60.68% of 234 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.435 vs MEDP: 2.99

Medpace Holdings Cash-to-Debt Historical Data

The historical data trend for Medpace Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Medpace Holdings Cash-to-Debt Chart

Medpace Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.92 2.41 3.52 0.15 1.73

Medpace Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.20 0.67 1.73 2.99

Competitive Comparison of Medpace Holdings's Cash-to-Debt

For the Diagnostics & Research subindustry, Medpace Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Cash-to-Debt falls into.



Medpace Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Medpace Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Medpace Holdings's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medpace Holdings  (NAS:MEDP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Medpace Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings (Medpace Holdings) Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Executives
Susan E Burwig officer: Exec. VP, Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
August J. Troendle director, 10 percent owner, officer: CEO 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Investors, Llc 10 percent owner 4620 WESLEY AVENUE, CINCINNATI OH 45212
Robert O. Kraft director ONE CVS DRIVE, WOONSOCKET RI 02895
Kevin M. Brady officer: CFO & Treasurer MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Stephen P Ewald officer: General Counsel & Corp. Secy. C/O MEDPACE HOLDINGS,INC., 5375 MEDPACE WAY, CINTINNATI OH 45227
Femida H. Gwadry-sridhar director 5375 MEDPACE WAY, CINCINNATI OH 45227
Ashley M. Keating director 5375 MEDPACE WAY, CINCINNATI OH 45227
Davenport Fred B Jr director
Brian T Carley director C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Mccarthy Cornelius P. Iii director 5375 MEDPACE WAY, CINCINNATI OH 45227
Jesse J Geiger officer: CFO & COO, Lab Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Tom C King director 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Limited Partnership 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT, CHANNEL ISLANDS Y7 GY1 3PP
Cinven Capital Management (v) General Partner Ltd 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT Y7 GY1 3PP